EQL Pharma AB preliminarily announces very strong outcome for the third quarter and reports continued strongly increasing order intake

EQL Pharma AB (“EQL” or “the Company”) publishes in advance an update regarding the third quarter before the planned quarterly report on February 16, 2022 and announces that order intake during the ongoing fourth quarter continues to increase sharply.

The preliminary summary for the third quarter (period October - December 2021) shows that net sales amounted to approximately SEK 117 million (SEK 29.61 million) and that EBIT amounted to approximately SEK 18 million (SEK 2.35 million). The increase in sales is explained by a very strong demand for the Company's self-tests for Covid-19, which account for approximately 70 percent of net sales during the quarter. Most of the self-tests have been sold during the last weeks of December.

For the current fourth quarter, we see an order intake that is even stronger for our self-tests and therefore assess that both sales and EBIT for the fourth quarter will exceed the outcome for the third quarter of the year by more than 50%.

All figures in this press release are preliminary and unaudited.

This disclosure contains information that EQL Pharma is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 13-01-2022 08:30 CET.

For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

Eql Pharma AB (Publ) briefly
EQL Pharma AB specializes in developing and selling generics, ie pharmaceuticals that are medically equivalent to reference pharmaceuticals. The company currently has upwards of 20 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2021 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.